These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 33578191)

  • 1. Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study.
    Cree BAC; Bowen JD; Hartung HP; Vermersch P; Hughes B; Damian D; Hyvert Y; Dangond F; Galazka A; Grosso M; Jones DL; Leist TP
    Mult Scler Relat Disord; 2021 Apr; 49():102695. PubMed ID: 33578191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study.
    Freedman MS; Coyle PK; Comi G; L Scarberry S; Damian D; Hyvert Y; Dangond F; Galazka A; Jack D; Lebson LA; Leist TP
    Mult Scler J Exp Transl Clin; 2021; 7(1):2055217321990852. PubMed ID: 33717501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.
    Leist TP; Comi G; Cree BA; Coyle PK; Freedman MS; Hartung HP; Vermersch P; Casset-Semanaz F; Scaramozza M;
    Lancet Neurol; 2014 Mar; 13(3):257-67. PubMed ID: 24502830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study.
    Freedman MS; Leist TP; Comi G; Cree BA; Coyle PK; Hartung HP; Vermersch P; Damian D; Dangond F
    Mult Scler J Exp Transl Clin; 2017; 3(4):2055217317732802. PubMed ID: 29051829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum neurofilament light chain correlations in patients with a first clinical demyelinating event in the REFLEX study: a
    Kuhle J; Leppert D; Comi G; de Stefano N; Kappos L; Freedman MS; Seitzinger A; Roy S
    Ther Adv Neurol Disord; 2024; 17():17562864241239101. PubMed ID: 38560407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS.
    de Stefano N; Barkhof F; Montalban X; Achiron A; Derfuss T; Chan A; Hodgkinson S; Prat A; Leocani L; Schmierer K; Sellebjerg F; Vermersch P; Wiendl H; Keller B; Roy S;
    Neurol Neuroimmunol Neuroinflamm; 2022 Jul; 9(4):. PubMed ID: 35701185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.
    Comi G; Cook SD; Giovannoni G; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Hamlett AC; Viglietta V; Greenberg SJ
    J Neurol; 2013 Apr; 260(4):1136-46. PubMed ID: 23263473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous interferon β-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study.
    Comi G; De Stefano N; Freedman MS; Barkhof F; Uitdehaag BM; de Vos M; Marhardt K; Chen L; Issard D; Kappos L
    J Neurol Neurosurg Psychiatry; 2017 Apr; 88(4):285-294. PubMed ID: 28039317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.
    Ali S; Paracha N; Cook S; Giovannoni G; Comi G; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Greenberg S; Scott DA; Joyeux A;
    Clin Drug Investig; 2012 Jan; 32(1):15-27. PubMed ID: 22017519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
    Giovannoni G; Cook S; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Hamlett A; Viglietta V; Greenberg S;
    Lancet Neurol; 2011 Apr; 10(4):329-37. PubMed ID: 21397565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishing the diagnosis of multiple sclerosis in Croatian patients with clinically isolated syndrome: 2010 versus 2017 McDonald criteria.
    Habek M; Pavičić T; Ruška B; Pavlović I; Gabelić T; Barun B; Adamec I; Crnošija L; Krbot Skorić M
    Mult Scler Relat Disord; 2018 Oct; 25():99-103. PubMed ID: 30059896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study.
    Freedman MS; De Stefano N; Barkhof F; Polman CH; Comi G; Uitdehaag BM; Casset-Semanaz F; Hennessy B; Lehr L; Stubinski B; Jack DL; Kappos L
    J Neurol; 2014 Mar; 261(3):490-9. PubMed ID: 24413638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta-1a.
    Battaglini M; Vrenken H; Tappa Brocci R; Gentile G; Luchetti L; Versteeg A; Freedman MS; Uitdehaag BMJ; Kappos L; Comi G; Seitzinger A; Jack D; Sormani MP; Barkhof F; De Stefano N
    Eur J Neurol; 2022 Jul; 29(7):2024-2035. PubMed ID: 35274413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion of clinically isolated syndrome to multiple sclerosis: a prospective study.
    Kolčava J; Kočica J; Hulová M; Dušek L; Horáková M; Keřkovský M; Stulík J; Dostál M; Kuhn M; Vlčková E; Bednařík J; Benešová Y
    Mult Scler Relat Disord; 2020 Sep; 44():102262. PubMed ID: 32570179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study.
    Rammohan K; Giovannoni G; Comi G; Cook S; Rieckmann P; Soelberg Sørensen P; Vermersch P; Hamlett A; Kurukulasuriya N;
    Mult Scler Relat Disord; 2012 Jan; 1(1):49-54. PubMed ID: 25876451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis.
    Bartosik-Psujek H; Kaczyński Ł; Górecka M; Rolka M; Wójcik R; Zięba P; Kaczor M
    Mult Scler Relat Disord; 2021 Apr; 49():102769. PubMed ID: 33516133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.
    Giovannoni G; Soelberg Sorensen P; Cook S; Rammohan KW; Rieckmann P; Comi G; Dangond F; Hicking C; Vermersch P
    Mult Scler; 2019 May; 25(6):819-827. PubMed ID: 29716436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnetic Resonance Imaging Evidence Supporting the Efficacy of Cladribine Tablets in the Treatment of Relapsing-Remitting Multiple Sclerosis.
    Cortese R; Testa G; Assogna F; De Stefano N
    CNS Drugs; 2024 Apr; 38(4):267-279. PubMed ID: 38489020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis:
    Vermersch P; Galazka A; Dangond F; Damian D; Wong SL; Jack D; Harty G
    Curr Med Res Opin; 2021 Mar; 37(3):459-464. PubMed ID: 33331183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.